S5 Table. AEs reported in study patients (n=20)

Type of adverse event	Pembrolizumab monotherapy (n=8)		SNK combination[a)] (n=12)	
	Any grade	Grade 3-5	Any grade	Grade 3-5
All AEs	8 (100)	2 (25.0)	12 (100)	1 (8.3)
Treatment-related AEs				
Pembrolizumab-related AEs	6 (75.0)	1 (12.5)	11 (91.7)	0
SNK01-related AEs	0	0	0	0
Common AEs occurring in ≥2 patients				
Anorexia	3 (37.5)	0	4 (33.3)	0
Myalgia	2 (25.0)	1 (12.5)	1 (8.3)	0
Arthralgia	1 (12.5)	1 (12.5)	2 (16.7)	0
Pneumonia	0	0	3 (25.0)	0
Back pain	1 (12.5)	0	2 (16.7)	0
Hyperkalemia	0	0	3 (25.0)	0
Fatigue	2 (25.0)	0	0	0
Insomnia	0	0	2 (16.7)	0
Urticaria	0	0	2 (16.7)	0
Headache	0	0	2 (16.7)	0
Immune-related AEs	0	0	5 (41.7)	0
Hyperthyroidism	0	0	3 (25.0)	0
Hypothyroidism	0	0	3 (25.0)	0
Pneumonitis	0	0	1 (8.3)	0

Values are presented as number (%). AE, adverse event. [a)]The two patients who were randomized to a SNK combination group but discontinued treatment prior to receiving their first dose of SNK01 due to SAE after pembrolizumab treatment (myalgia and pneumonia, respectively) were analyzed as the pembrolizumab monotherapy group in this table.